Cassiopea SpA introduced Winlevi® to the market for acne vulgaris therapy.

 The high prevalence of skin disease, in particular acne, is represented in North America. As a result, the area is projected in the global market for acne vulgaris treatment to hold the dominant spot. In the US, ACNE affects between 40 and 50 million people, according to the American Medical Association. While acne affects primarily teenagers, in children and adults, it also occurs. In one survey, 54% of women and 40% of men over 25 years of age have some degree of facial acne.

The growth in the acne vulgaris market increases the perception of acne in young people combined with the increase in disposable income. Manufacturers are concentrating on implementing effective acne vulgaris therapies, which will also boost business growth. In September 2020, Adapalene Gel USP 0.3 percent, a topical retinoid for acne vulgaris in patients aged 12 years and over, announced the launch of their bioequivalent and therapeutically equivalent to Differin Gel 0.3 percent, a therapeutically equivalent medication. Also, Cassiopaean SpA's Italian acne treatment Winlevi was approved by the US Food and Drug Administration (FDA) in August 2020. (clascoterone cream 1 percent). Winlevi is the first acne drug to gain regulatory approval in the United States through a novel mechanism of action.

1. The U.S. Food and Drug Administration has approved the New Drug Request for ARAZLOTM (tazarotene) lotion of 0.045 percent to treat topical acne vulgaris in patients aged nine years and older in December 2019 by Bausch Health Companies Inc. and its dermatological firm, The Ortho Dermatologics, the medical health care company of prescribed dermatology.

2. In August 2020, the Cassiopea SpA announced the approval of Winlevi® (clascoterone cream 1%) for acne treatment in patients aged 12 and older by the United States Food and Drug Administration (FDA).

3. The research combination of a proprietary combination of 3% enveloped benzoyl peroxide and the encapped 0.1% tretinoin cream for the treatment of acne vulgaris was launched in December 2020 by Sol-Gel technologies, Ltd. New Drug Application (NDA) for Twyneo® (benzoyl peroxide and Tretinoin).

Treatment with acne vulgaris is crucial for clean and sound skin. Almost everyone in their lives is affected by this form of acne. The long-term health effects that could arise from this kind of skin disease also make Acne vulgaris treatment important. Acne vulgaris is a major skin condition that occurs when oil and dead skin cells block pores and cause inflammation. Common signs include whiteheads or blackheads, inflammation of the skin, acne scars, acne, and potential face scars.